HOME > BUSINESS
BUSINESS
- Tarlige Most Pitched Drug in April: Impact Track Survey
July 19, 2019
- BACE Inhibitor Elenbecestat Shows No Major Effect on Synaptic Function in Nonclinical Study: Eisai
July 19, 2019
- IPO Pending, StemRIM Looks to File World’s 1st Regeneration-Inducing Med Next Year: CEO
July 18, 2019
- Astellas Hitches Frequency’s Regenerative Hearing Loss Therapy Outside US
July 18, 2019
- Astellas/Seattle Genetics’ ADC Filed in US for Urothelial Cancer
July 18, 2019
- Halaven Bags China Approval for Breast Cancer: Eisai
July 18, 2019
- Ono’s Yamaguchi Plant Completed, Set to Go Live Next Spring
July 18, 2019
- Alexion Promotes Kimihiro Kasamo to Japan Chief
July 18, 2019
- Bayer Flatly Denies Its Employee’s Allegations in 2nd Oral Proceedings for Damage Suit
July 18, 2019
- Takeda Gears Up for Clinical Testing of 1st iPS-Derived CAR-T, Eyes Trial Launch in 2021
July 17, 2019
- Takeda Launches New Manufacturing Facility for Ninlaro at Irish Plant
July 17, 2019
- JT’s HIF-PH Inhibitor Enarodustat Non-Inferior to Nesp
July 16, 2019
- 60% of Japan Diabetes Patients Bear CV Risk Factors, or Suffered Event: Novo
July 16, 2019
- Simone Thomsen Tapped as Lilly Japan Chief; Patrik Jonsson to Take Big Job at HQ
July 12, 2019
- Ono Snags Stanford Spinout’s Macrophage Checkpoint in Asia
July 12, 2019
- PeptiStar’s Peptides Manufacturing Plant Completed
July 11, 2019
- Eisai Opens New Dementia Research Center in Cambridge
July 11, 2019
- Tarlige Most Promoted Drug for GPs in March: Anterio
July 11, 2019
- Astellas’ JAK Inhibitor Smyraf Now Available for RA
July 11, 2019
- Fujifilm, Axcelead Team Up for iPS Cell-Based Drug Discovery Support
July 11, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
